Grifols gana un 28% más y acelera en el tercer trimestre

Grifols reported a 28% increase in profit and faster growth in the third quarter of the year. The company's revenue reached 5.614 million euros in the first nine months of the year, a 28% increase, driven by the performance of its plasma division. Sales and earnings grew significantly in the third quarter, with a 8.4% rise to 2.400 million euros.

The biopharma business, which manufactures and sells hemoderivatives, remains the main driver of Grifols' growth, with a 7.1% increase in the first nine months of the year. This growth is attributed to high demand for immunoglobulins in key markets and contributions from alfa-1 and specialized proteins franchises. However, albumin revenue decreased by 13.9% for the year due to negative effects from the Chinese market, where regulatory factors and high inventory levels continue to hinder sales.

Grifols is diversifying and optimizing its sales channels in partnership with its local partner, Shanghai RAAS. The diagnostics business contracted by 7% after the completion of its alliance with QuidelOrtho. Adjusted EBITDA reached 1.392 million euros by the end of September, a 5.0% increase at constant rates, with a 24.8% margin, including the effect of currencies.

Reported EBITDA was 1.292 million euros, a 0.15% decrease at constant rates. The company attributes the improvement in profitability to increased volumes, growth in subcutaneous immunoglobulins, and optimization of the plasma center network. Nacho Abia, Grifols' CEO, announced the closure of 29 centers in the US to reduce costs in April.

The company reduced its financial loss by 20% to -371 million euros, also contributing to the improvement in net profit. Grifols' free cash flow before merger and acquisition transactions increased to 298 million euros in the nine-month accumulated period, and net financial debt closed the period at 7.706 million euros (-3.5%). As of September 30, 2026, the net leverage ratio decreased to 3.98 times EBITDA, down from 4.2 times in the same period of 2025.

Grifols has reaffirmed its financial targets for the entire year, predicting a free cash flow before mergers and acquisitions between 500 million and 575 million euros at year-end and an EBITDA growth between 5% and 9%. Abia stated, "The third-quarter results reflect the sustained execution of our plan, with growth in our main businesses leading to higher profitability and cash generation."

Grifols announced a dividend payment of 0.15 euros per share, totaling around 100 million euros for 2026.